Screener Summaries Updates Institutions Sign In More Updates › Other Events › PLRZ Other Events · Jun 15, 2026
Polyrizon Ltd. announced on June 15, 2026, the advancement of its NASARIX™ development through a key human study… PLRZ Polyrizon Ltd.
Polyrizon Ltd. announced on June 15, 2026, the advancement of its NASARIX™ development through a key human study designed to characterize nasal residence time and support the FDA regulatory pathway. The study aims to provide critical data for the product's clinical and regulatory progression. Polyrizon Ltd. is a biotechnology company focused on developing nasal delivery technologies.
More from Polyrizon Ltd. Polyrizon completes enrollment of all 120 patients in U.S. clinical study of NASARIX Allergy Blocker Oct 27, 2026 Polyrizon raises $4M in registered direct offering, reports $1.4M net loss for six months ended June 30 Sep 28, 2026 Polyrizon Ltd. closed a registered direct offering and concurrent private placement on September 4, 2026, raising… Sep 4, 2026 On September 3, 2026, Polyrizon Ltd. entered into a securities purchase agreement to raise approximately $4.0 million… Sep 4, 2026 Polyrizon Ltd. announced on August 20, 2026, that it has completed contracting with all five U.S. clinical sites for… Aug 20, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
